Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery.
Nature Communications
Havugimana, Pierre C PC; Goel, Raghuveera Kumar RK; Phanse, Sadhna S; Youssef, Ahmed A; Padhorny, Dzmitry D; Kotelnikov, Sergei S; Kozakov, Dima D; Emili, Andrew A
Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
Oncotarget
Riveiro, Maria E ME; Astorgues-Xerri, Lucile L; Vazquez, Ramiro R; Frapolli, Roberta R; Kwee, Ivo I; Rinaldi, Andrea A; Odore, Elodie E; Rezai, Keyvan K; Bekradda, Mohamed M; Inghirami, Giorgio G; D'Incalci, Maurizio M; Noel, Kay K; Cvitkovic, Esteban E; Raymond, Eric E; Bertoni, Francesco F
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
British Journal Of Cancer
Mahoney, C L CL; Choudhury, B B; Davies, H H; Edkins, S S; Greenman, C C; Haaften, G van Gv; Mironenko, T T; Santarius, T T; Stevens, C C; Stratton, M R MR; Futreal, P A PA